Lorlatinib (NSCLC) - Benefit assessment according to §35a Social Code Book V

Report documents

1. Extract of dossier assessment

   Lorlatinib (NSCLC) - Benefit assessment according to §35a Social Code Book V

   published on

   01.06.2022

   Document type

   PDF document, 678 kB, EN, not accessible

   Download file : Extract of dossier assessment (PDF document, 678 kB, EN, not accessible)
2. Dossier assessment

   Lorlatinib (NSCLC) - Benefit assessment according to §35a Social Code Book V

   published on

   01.06.2022

   Document type

   PDF document, 2 MB, DE, not accessible

   Download file : Dossier assessment (PDF document, 2 MB, DE, not accessible)

Dossier assessment

Project details

Project no.

A22-31

Commission

Commission awarded on 25.03.2022 by the Federal Joint Committee (GBA).

Report type

Dossier assessment

Status

Commission completed

Department/Division

Drug Assessment

Topic

Cancer

Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

Connected Projects

1. Dossier assessment

   Lorlatinib (NSCLC) - Benefit assessment according to §35a Social Code Book V

   Project no.

   A19-48

   Last updated

   02.09.2019

   Status: Commission completed